 SALT LAKE CITY, Aug. 12, 2022 GLOBE NEWSWIRE -- Clene Inc. NASDAQ: CLNN along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15. 